Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharming Group ( (PHAR) ) has shared an update.
On June 24, 2025, Pharming Group announced it will host a webcast to discuss a new study published in the journal Cell, which advances the functional classification of genetic variants of uncertain significance (VUS) to improve the diagnosis of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The study, led by researchers from Columbia University, identified over 100 new variants linked to APDS, suggesting the condition may be more prevalent than previously thought. This development is expected to aid genetic testing laboratories in reclassifying VUSs, accelerating the diagnostic process for many patients. The webcast, featuring insights from Dr. Joshua Milner, will take place on June 30, 2025.
The most recent analyst rating on (PHAR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall stock score reflects a blend of solid earnings growth prospects and strategic advancements, counterbalanced by current financial instability and high valuation concerns. Notable revenue growth and strategic initiatives from the earnings call significantly enhance the score, but ongoing profitability challenges and fluctuating cash flows remain major risks.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative products for the treatment of rare and life-threatening diseases. The company is known for its work in the field of immunology, particularly with products like leniolisib, a targeted treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
Average Trading Volume: 3,930
Technical Sentiment Signal: Strong Buy
Current Market Cap: $718.5M
See more insights into PHAR stock on TipRanks’ Stock Analysis page.